Am J Psychiatry 156:1065-1068, July 1999
© 1999 American Psychiatric Association
Including Children and Adolescents With Schizophrenia in Medication-Free Research
Sanjiv Kumra, M.D., F.R.C.P.,
Claudia Briguglio, R.N., M.N.,
Marge Lenane, M.S.W.,
Laura Goldhar,
Jeffrey Bedwell, B.S.,
Julia Venuchekov,
Leslie K. Jacobsen, M.D., and
Judith L. Rapoport, M.D.
OBJECTIVE: There has been an increasing focus on the ethical issues raised by studies requiring the withdrawal of effective medication in schizophrenic adults. This article examines the risks and benefits of a medication-free period for pediatric patients with treatment-refractory schizophrenia who are participating in an ongoing study. METHOD: Between April 1993 and March 1998, 31 children and adolescents were admitted with a diagnosis of treatment-resistant, childhood-onset schizophrenia. Parental consent was obtained so that patients could participate in a medication-free research period. Patients were evaluated at screening, at the end of a 4-week washout, at the completion of a 6- to 8-week atypical neuroleptic trial, and at a 2- to 4-year follow-up. RESULTS: At the completion of a 4-week drug-free period, seven patients (23%) were diagnosed with another disorder on the basis of data gained from the drug-free period and their lack of schizophrenic symptoms. Their revised diagnoses were posttraumatic stress disorder (N=1), an atypical psychosis labeled "multidimensionally impaired" (N=4), and personality disorder (N=2). At follow-up, three of these patients remained free of neuroleptic therapy. For eight patients (26%), the washout was curtailed because of rapid and severe deterioration of their schizophrenic symptoms. CONCLUSIONS: For children and adolescents with treatment-refractory schizophrenia, a medication-free period can be conducted safely for at least 4 weeks for inpatients. Such trials are useful on clinical grounds and for providing homogeneous patient groups for research. This study also highlights the necessity of having access to hospitalization to observe children and adolescents with psychotic symptoms while medication free.
This article has been cited by other articles:
|
|
|
|
 
N. Gogtay
Cortical Brain Development in Schizophrenia: Insights From Neuroimaging Studies in Childhood-Onset Schizophrenia
Schizophr Bull,
January 1, 2008;
34(1):
30 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumra, J. V. Oberstar, L. Sikich, R. L. Findling, J. M. McClellan, S. Vinogradov, and S. Charles Schulz
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Schizophr Bull,
January 1, 2008;
34(1):
60 - 71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Vidal, J. L. Rapoport, K. M. Hayashi, J. A. Geaga, Y. Sui, L. E. McLemore, Y. Alaghband, J. N. Giedd, P. Gochman, J. Blumenthal, et al.
Dynamically Spreading Frontal and Cingulate Deficits Mapped in Adolescents With Schizophrenia
Arch Gen Psychiatry,
January 1, 2006;
63(1):
25 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Pappadopulos, J. C. MacIntyre II, M. L. Crismon, R. L. Findling, R. P. Malone, A. Derivan, N. Schooler, L. Sikich, L. Greenhill, S. B. Schur, et al.
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY) Part II
Focus,
October 1, 2004;
2(4):
608 - 624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Thompson, C. Vidal, J. N. Giedd, P. Gochman, J. Blumenthal, R. Nicolson, A. W. Toga, and J. L. Rapoport
From the Cover: Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia
PNAS,
September 25, 2001;
98(20):
11650 - 11655.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
